Cobimetinib + Atezolizumab Active in BRAF Wild-type Melanoma

Share this content:
Cobimetinib in combination with atezolizumab was active and associated with a median progression-free survival of 15.7 months.
Cobimetinib in combination with atezolizumab was active and associated with a median progression-free survival of 15.7 months.

Cobimetinib in combination with atezolizumab was active and associated with a median progression-free survival of 15.7 months among patients with BRAF wild-type non-ocular melanoma, according to data presented at the Society for Melanoma Research 2016 Congress in Boston, Massachusetts.1

In the melanoma cohort of a phase 1b trial of cobimetinib and atezolizumab, investigators enrolled 22 patients with metastatic disease, including 20 patients with non-ocular melanoma. Of those, 10 had BRAF V600 mutation-positive disease and 10 had BRAF wild-type disease.

Results showed that 45% of the 20 patients with non-ocular melanoma achieved a partial response, including 5 with BRAF wild-type melanoma. Median duration of response was 14.9 months and median progression-free survival was 12 months overall. Median overall survival has not yet been reached.

Subgroup analysis demonstrated that median progression-free survival was 15.7 months among those with BRAF wild-type melanoma and 11.9 months among those with BRAF mutation-positive disease.

Combination therapy was generally well tolerated, with 59% of patients reporting treatment-related grade 3 to 4 adverse events but no grade 5 toxicities.

Based on these findings, Genentech plans to evaluate cobimetinib plus atezolizumab compared with a PD-1 inhibitor among treatment-naive patients with BRAF wild-type advanced melanoma in a phase 3 trial.

RELATED: For First-line Therapy of BRAF-mutant Melanoma, PD-1 Inhibitors May Be Preferred

Cobimetinib is a kinase inhibitor approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for advanced bladder cancer and non-small cell lung cancer.

Reference

  1. Exelixis announces presentation of cobimetinib combination therapy data at the Society for Melanoma Research 2016 Congress that support Genentech's planned phase 3 pivotal trials. Exelixis website. http://www.exelixis.com/investors-media/press-releases. Updated November 7, 2016. Accessed November 7, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs